[Management of hepatitis B].
Treatment of chronic hepatitis B needs to consider two aspects. First, a certain proportion of patients will spontaneously undergo a stable remission of the underlying liver disease, i.e. without therapeutic intervention, on occasion of the HBeAg --> anti-HBe seroconversion. Second, all drugs that have been used so far in the treatment of HBV have rarely resulted in the definitive eradication of the viral infection, i.e. a permanent disappearance of HBsAg with development of anti-HBs. Thus, the most reasonable, albeit surrogate endpoint of treatment is the acceleration towards HBeAg --> anti-HBe seroconversion and/or the stable suppression of HBV replication at levels below 500000 copies/ml, which is associated with disappearance of intrahepatic necrosis and inflammation and slowing down of the fibrosis progression. Two drugs are currently available--interferon-alpha and lamivudine--and a third antiviral compound (adefovir dipivoxil) will soon appear in the market. Advantages and disadvantages of different therapeutic options are discussed below.